Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 80+ pipeline drugs in the Cystic Fibrosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Cystic Fibrosis Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Cystic Fibrosis Therapeutics Market.
The report provides a detailed description of the Cystic Fibrosis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Cystic Fibrosis Clinical Trial Activities and Regulatory Developments in the domain @
www.delveinsight.com/report-store/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Cystic Fibrosis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Cystic Fibrosis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Cystic Fibrosis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Cystic Fibrosis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Cystic Fibrosis Therapeutics Domain @
www.delveinsight.com/report-store/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Cystic Fibrosis Therapeutics Analysis
The current drugs for Cystic Fibrosis focus on symptomatic improvement, complication prevention as well as more recently, protein rectifiers to correct underlying structural and functional abnormalities. The paradigm includes inhaled antibiotics for treatment of chronic lung infection, mucolytics for reducing the viscosity of pulmonary mucus, pancreatic enzyme replacement therapy (PERT) for the treatment of CF-associated exocrine pancreatic insufficiency (PPI), and CFTR modulators for enhancing CFTR function, targeting the underlying cause of the disease.
To further improve the treatment outlook, there are approximately 75 noteworthy companies actively involved in the development of therapies for Cystic Fibrosis. Among these, Algi Pharma stands out as a key player, with its Cystic Fibrosis drug candidates advancing to the most advanced stage, Phase II clinical trials.
Cystic Fibrosis Companies in the Therapeutics Market Include:
Some of the leading companies in the Cystic Fibrosis Market include Axentis Pharma AG, AbbVie, AlgiPharma, AstraZeneca, Atlantic Healthcare, Calithera Biosciences, EmphyCorp, Galapagos NV, GlaxoSmithKline, Horizon Therapeutics, Krystal Biotech, Novartis, PathBioAnalytics, Reveragen Biopharma, Santhera Pharmaceuticals, SpliSense, TranslateBio, Verona Pharma, Vertex Pharmaceuticals, and many others.
Emerging and Marketed Cystic Fibrosis Therapies Covered in the Report Include:
• OligoG: Algi Pharma
• Ensifentrine: Verona Pharma
• MRT5005: Translate Bio
• CB280: Calithera Biosciences
• KB407 : Krystal Biotech
• SPL84231: SpliSense
Get an in-depth Assessment of the Emerging Therapies and Cystic Fibrosis Companies Actively Working in the Market @
www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Cystic Fibrosis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates
Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Request for Sample PDF to Understand More About the Cystic Fibrosis Treatment Outlook and Future Perspectives @
www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Cystic Fibrosis Current Treatment Patterns
4. Cystic Fibrosis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Cystic Fibrosis Late-Stage Products (Phase-III)
7. Cystic Fibrosis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cystic Fibrosis Discontinued Products
13. Cystic Fibrosis Product Profiles
14. Cystic Fibrosis Companies
15. Cystic Fibrosis Drugs
16. Dormant and Discontinued Products
17. Cystic Fibrosis Unmet Needs
18. Cystic Fibrosis Future Perspectives
19. Cystic Fibrosis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings @
www.delveinsight.com/sample-request/cystic-fibrosis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: [email protected]
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
